Exact Mass: 403.2642

Exact Mass Matches: 403.2642

Found 409 metabolites which its exact mass value is equals to given mass value 403.2642, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Pleurostyline

Pleurostyline

C25H29N3O2 (403.226)


   

Spergualin

Spergualin

C17H37N7O4 (403.2907)


D000970 - Antineoplastic Agents

   
   

3,4-Dihydroxy-tamoxifen

4-[(1E)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]benzene-1,2-diol

C26H29NO3 (403.2147)


3,4-Dihydroxy-tamoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)

   

N-Palmitoyl phenylalanine

(2S)-2-[(1-hydroxyhexadecylidene)amino]-3-phenylpropanoic acid

C25H41NO3 (403.3086)


N-palmitoyl phenylalanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Phenylalanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl phenylalanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl phenylalanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

3,11-Dihydroxytetradecanoylcarnitine

3-[(3,11-dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H41NO6 (403.2934)


3,11-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,11-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,11-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,11-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,7-Dihydroxytetradecanoylcarnitine

3-[(3,7-dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H41NO6 (403.2934)


3,7-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,7-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,7-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,7-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,13-Dihydroxytetradecanoylcarnitine

3-[(3,13-dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H41NO6 (403.2934)


3,13-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,13-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,13-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,13-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,8-Dihydroxytetradecanoylcarnitine

3-[(3,8-dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H41NO6 (403.2934)


3,8-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,8-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,8-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,8-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,4-Dihydroxytetradecanoylcarnitine

3-[(3,4-dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H41NO6 (403.2934)


3,4-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,4-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,4-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,5-Dihydroxytetradecanoylcarnitine

3-[(3,5-dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H41NO6 (403.2934)


3,5-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,5-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,5-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,5-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,10-Dihydroxytetradecanoylcarnitine

3-[(3,10-Dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C21H41NO6 (403.2934)


3,10-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,10-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,10-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,10-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,12-Dihydroxytetradecanoylcarnitine

3-[(3,12-Dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C21H41NO6 (403.2934)


3,12-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,12-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,12-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,12-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,6-Dihydroxytetradecanoylcarnitine

3-[(3,6-dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H41NO6 (403.2934)


3,6-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,6-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,6-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,6-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,9-Dihydroxytetradecanoylcarnitine

3-[(3,9-Dihydroxytetradecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C21H41NO6 (403.2934)


3,9-Dihydroxytetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,9-Dihydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,9-Dihydroxytetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3,9-Dihydroxytetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Arachidonoyl Valine

2-[(1-Hydroxyicosa-5,8,11,14-tetraen-1-ylidene)amino]-3-methylbutanoate

C25H41NO3 (403.3086)


N-arachidonoyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Eicosapentaenoyl Threonine

3-hydroxy-2-(icosa-5,8,11,14,17-pentaenamido)butanoic acid

C24H37NO4 (403.2722)


N-eicosapentaenoyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Threonine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

metergoline

benzyl N-({6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl}methyl)carbamate

C25H29N3O2 (403.226)


   

Spergualin

N-[({4-[(3-aminopropyl)amino]butyl}-C-hydroxycarbonimidoyl)(hydroxy)methyl]-7-carbamimidamido-3-hydroxyheptanimidate

C17H37N7O4 (403.2907)


   

Neoperiphylline

Neoperiphylline

C25H29N3O2 (403.226)


   

Dihydrotubingensin A

Dihydrotubingensin A

C28H37NO (403.2875)


   

2-amino-3,4,14-trihydroxy-2-hydroxymethyl-6-eicosenoic acid

2-amino-3,4,14-trihydroxy-2-hydroxymethyl-6-eicosenoic acid

C21H41NO6 (403.2934)


   
   

Oxodaphnigraciline

Oxodaphnigraciline

C23H33NO5 (403.2359)


   

Mycestericin C

Mycestericin C

C21H41NO6 (403.2934)


   

Gomandonine 13-O-acetate

Gomandonine 13-O-acetate

C23H33NO5 (403.2359)


   
   

N-Octadecanoylanthranilic acid

N-Octadecanoylanthranilic acid

C25H41NO3 (403.3086)


   

CB-25

N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-undecanamide

C25H41NO3 (403.3086)


   

Maybridge3_006700

Maybridge3_006700

C25H29N3O2 (403.226)


   

Maybridge4_004497

Maybridge4_004497

C25H29N3O2 (403.226)


   

daphnezomic acid

daphnezomic acid

C24H37NO4 (403.2722)


   

4-phenyl-9-(3-phenyl-acryloyl)-1,5,9-triaza-cyclotridec-10-en-2-one|Neoperiphyllin|Neoperiphylline

4-phenyl-9-(3-phenyl-acryloyl)-1,5,9-triaza-cyclotridec-10-en-2-one|Neoperiphyllin|Neoperiphylline

C25H29N3O2 (403.226)


   
   
   

alachalasin E

alachalasin E

C23H33NO5 (403.2359)


   
   

Holacetin-O-acetat

Holacetin-O-acetat

C25H41NO3 (403.3086)


   

Dihydrotubingensin B

Dihydrotubingensin B

C28H37NO (403.2875)


   

daphniglaucin C

daphniglaucin C

C23H33NO5 (403.2359)


   
   

17-ketoeujindole|17-oxoeujindole

17-ketoeujindole|17-oxoeujindole

C28H37NO (403.2875)


   

12-hydroxygymnastatin N

12-hydroxygymnastatin N

C23H33NO5 (403.2359)


   

stemocochinin

stemocochinin

C23H33NO5 (403.2359)


   

8,21-dehydro-17-hydroxyeujindole

8,21-dehydro-17-hydroxyeujindole

C28H37NO (403.2875)


   

Ancistrobrevine C

Ancistrobrevine C

C26H29NO3 (403.2147)


   

macrodumine C|methyl (4S,6R,6?S,10aR,11S)-6?-ethyl-2,3,4,5,5?,6,6?,7,8,10-decahydro-6,6?-dihydroxy-2-methyl-1H,4?H-spiro[4,10a-methanopentaleno[1,6-cd]azonine-11,3?-pyran]-9-carboxylate

macrodumine C|methyl (4S,6R,6?S,10aR,11S)-6?-ethyl-2,3,4,5,5?,6,6?,7,8,10-decahydro-6,6?-dihydroxy-2-methyl-1H,4?H-spiro[4,10a-methanopentaleno[1,6-cd]azonine-11,3?-pyran]-9-carboxylate

C23H33NO5 (403.2359)


   

2-(Octadecanoylamino)benzoic acid

2-(Octadecanoylamino)benzoic acid

C25H41NO3 (403.3086)


   

daphnioldhamine A

daphnioldhamine A

C23H33NO5 (403.2359)


   

macrodumine A|methyl (4S,6?S,8aR,9R,10aR,11S)-6?-ethyl-2,3,4,5,5?,6,6?,7,8,8a,9,10-dodecahydro-6?-hydroxy-2-methyl-7-oxo-1H,4?H-spiro[4,10a-methanopentaleno[1,6-cd]azonine-11,3?-pyran]-9-carboxylate

macrodumine A|methyl (4S,6?S,8aR,9R,10aR,11S)-6?-ethyl-2,3,4,5,5?,6,6?,7,8,8a,9,10-dodecahydro-6?-hydroxy-2-methyl-7-oxo-1H,4?H-spiro[4,10a-methanopentaleno[1,6-cd]azonine-11,3?-pyran]-9-carboxylate

C23H33NO5 (403.2359)


   

(2R,3R,4bR,6aS,12bS,12cS,14aS)-4b-deoxypenijanthine A

(2R,3R,4bR,6aS,12bS,12cS,14aS)-4b-deoxypenijanthine A

C27H33NO2 (403.2511)


   

crambescidin acid

crambescidin acid

C22H33N3O4 (403.2471)


   

hemsleyaconitine G|rel-(2R,3S,4aR,8S,11S)-13-ethyl-1,3,4,5,6,8,9,10,11,11b-decahydro-3,11-dimethoxy-8-(methoxymethyl)-2H-2,4a-methano-8,11a-(methanoiminomethano)dibenzo[a,c][7]annulen-15-one

hemsleyaconitine G|rel-(2R,3S,4aR,8S,11S)-13-ethyl-1,3,4,5,6,8,9,10,11,11b-decahydro-3,11-dimethoxy-8-(methoxymethyl)-2H-2,4a-methano-8,11a-(methanoiminomethano)dibenzo[a,c][7]annulen-15-one

C24H37NO4 (403.2722)


   

alachalasin B

alachalasin B

C23H33NO5 (403.2359)


   

threonylarginyllysine

threonylarginyllysine

C16H33N7O5 (403.2543)


   

tryptophylalanyllysine

tryptophylalanyllysine

C20H29N5O4 (403.2219)


   
   

lysylglutamyllysine

lysylglutamyllysine

C17H33N5O6 (403.2431)


   
   
   
   

arginylthreonyllysine

arginylthreonyllysine

C16H33N7O5 (403.2543)


   

glutaminylthreonylarginine

glutaminylthreonylarginine

C15H29N7O6 (403.2179)


   
   

threonyllysylarginine

threonyllysylarginine

C16H33N7O5 (403.2543)


   

Metergoline phenylmethyl ester

Metergoline phenylmethyl ester

C25H29N3O2 (403.226)


   

Val Ser Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxypropanamido]propanamido]hexanoic acid

C17H33N5O6 (403.2431)


   
   

threonylglutaminylarginine

threonylglutaminylarginine

C15H29N7O6 (403.2179)


   
   
   
   

Metergoline

Metergoline phenylmethyl ester

C25H29N3O2 (403.226)


An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7. G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist relative retention time with respect to 9-anthracene Carboxylic Acid is 0.923 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.918 Metergoline is a serotonin (5-HT) receptor and dopamine receptors antagonist, with pKis of 8.64, 8.75 and 8.75 for 5-HT2A, 5-HT2B and 5-HT2C, respectively. Metergoline is a high-affinity ligand for the h5-HT7 receptor, with a Ki of 16 nM. Metergoline is also a reversible neural Na+ channels inhibitor. Metergoline is commonly used for the research of seasonal affective disorder, prolactin hormone regulation[1][2][3].

   

2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid

NCGC00380823-01!2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid

C25H41NO3 (403.3086)


   

C24H37NO4_(7E)-11-Hydroxy-3-isobutyl-12-methoxy-4,5,8-trimethyl-2,3,3a,4,6a,9,10,11,12,13-decahydrocyclodeca[d]isoindole-1,14-dione

NCGC00380188-01_C24H37NO4_(7E)-11-Hydroxy-3-isobutyl-12-methoxy-4,5,8-trimethyl-2,3,3a,4,6a,9,10,11,12,13-decahydrocyclodeca[d]isoindole-1,14-dione

C24H37NO4 (403.2722)


   

2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid [IIN-based on: CCMSLIB00000845077]

NCGC00380823-01!2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid [IIN-based on: CCMSLIB00000845077]

C25H41NO3 (403.3086)


   

2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid [IIN-based: Match]

NCGC00380823-01!2-(14-methylpentadecanoylamino)-3-phenylpropanoic acid [IIN-based: Match]

C25H41NO3 (403.3086)


   

Ala Ala Arg Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C15H29N7O6 (403.2179)


   

Ala Ala Ser Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Ala Gly Arg Thr

(2S,3R)-2-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C15H29N7O6 (403.2179)


   

Ala Gly Thr Arg

(2S)-2-[(2S,3R)-2-{2-[(2S)-2-aminopropanamido]acetamido}-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Ala Lys Ser Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-hydroxypropanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Ala Lys Val Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-methylbutanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Ala Arg Ala Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]propanamido]-3-hydroxypropanoic acid

C15H29N7O6 (403.2179)


   

Ala Arg Gly Thr

(2S,3R)-2-{2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]acetamido}-3-hydroxybutanoic acid

C15H29N7O6 (403.2179)


   

Ala Arg Ser Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Ala Arg Thr Gly

2-[(2S,3R)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]acetic acid

C15H29N7O6 (403.2179)


   

Ala Ser Ala Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-hydroxypropanamido]propanamido]-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Ala Ser Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-hydroxypropanamido]hexanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Ala Ser Arg Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Ala Ser Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-hydroxypropanamido]-3-methylbutanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Ala Thr Gly Arg

(2S)-2-{2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]acetamido}-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Ala Thr Arg Gly

2-[(2S)-2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]acetic acid

C15H29N7O6 (403.2179)


   

Ala Val Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]hexanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Ala Val Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]-3-hydroxypropanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Gly Ala Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C15H29N7O6 (403.2179)


   

Gly Ala Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-(2-aminoacetamido)propanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Gly Ile Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]hexanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Gly Ile Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]-3-hydroxypropanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Gly Lys Ile Ser

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-methylpentanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Gly Lys Leu Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-4-methylpentanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Gly Lys Ser Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-hydroxypropanamido]-3-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Gly Lys Ser Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-hydroxypropanamido]-4-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Gly Lys Thr Val

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-hydroxybutanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Gly Lys Val Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-methylbutanamido]-3-hydroxybutanoic acid

C17H33N5O6 (403.2431)


   

Gly Leu Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]hexanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Gly Leu Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]-3-hydroxypropanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Gly Arg Ala Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]propanamido]-3-hydroxybutanoic acid

C15H29N7O6 (403.2179)


   

Gly Arg Thr Ala

(2S)-2-[(2S,3R)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-hydroxybutanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Gly Ser Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-(2-aminoacetamido)-3-hydroxypropanamido]-3-methylpentanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Gly Ser Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-hydroxypropanamido]hexanamido]-3-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Gly Ser Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-hydroxypropanamido]hexanamido]-4-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Gly Ser Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-hydroxypropanamido]-4-methylpentanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Gly Thr Ala Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-(2-aminoacetamido)-3-hydroxybutanamido]propanamido]-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Gly Thr Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-(2-aminoacetamido)-3-hydroxybutanamido]hexanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Gly Thr Arg Ala

(2S)-2-[(2S)-2-[(2S,3R)-2-(2-aminoacetamido)-3-hydroxybutanamido]-5-carbamimidamidopentanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Gly Thr Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-(2-aminoacetamido)-3-hydroxybutanamido]-3-methylbutanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Gly Val Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]hexanamido]-3-hydroxybutanoic acid

C17H33N5O6 (403.2431)


   

Gly Val Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-3-hydroxybutanamido]hexanoic acid

C17H33N5O6 (403.2431)


   
   

Ile Gly Lys Ser

(2S)-2-[(2S)-6-amino-2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}hexanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Ile Gly Ser Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}-3-hydroxypropanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Ile Lys Gly Ser

(2S)-2-{2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]acetamido}-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Ile Lys Ser Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-hydroxypropanamido]acetic acid

C17H33N5O6 (403.2431)


   
   

Ile Ser Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]acetamido}hexanoic acid

C17H33N5O6 (403.2431)


   

Ile Ser Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]hexanamido]acetic acid

C17H33N5O6 (403.2431)


   

Lys Ala Ser Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-hydroxypropanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Lys Ala Val Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-methylbutanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Lys Gly Ile Ser

(2S)-2-[(2S,3S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-methylpentanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Lys Gly Leu Ser

(2S)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-4-methylpentanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Lys Gly Ser Ile

(2S,3S)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-hydroxypropanamido]-3-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Lys Gly Ser Leu

(2S)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-hydroxypropanamido]-4-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Lys Gly Thr Val

(2S)-2-[(2S,3R)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-hydroxybutanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Lys Gly Val Thr

(2S,3R)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-methylbutanamido]-3-hydroxybutanoic acid

C17H33N5O6 (403.2431)


   

Lys Ile Gly Ser

(2S)-2-{2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]acetamido}-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Lys Ile Ser Gly

2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-hydroxypropanamido]acetic acid

C17H33N5O6 (403.2431)


   

Lys Leu Gly Ser

(2S)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]acetamido}-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Lys Leu Ser Gly

2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-hydroxypropanamido]acetic acid

C17H33N5O6 (403.2431)


   

Lys Ser Ala Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]propanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Lys Ser Gly Ile

(2S,3S)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]acetamido}-3-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Lys Ser Gly Leu

(2S)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]acetamido}-4-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Lys Ser Ile Gly

2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-methylpentanamido]acetic acid

C17H33N5O6 (403.2431)


   

Lys Ser Leu Gly

2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-4-methylpentanamido]acetic acid

C17H33N5O6 (403.2431)


   

Lys Ser Val Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-methylbutanamido]propanoic acid

C17H33N5O6 (403.2431)


   

Lys Thr Gly Val

(2S)-2-{2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]acetamido}-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Lys Thr Val Gly

2-[(2S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-methylbutanamido]acetic acid

C17H33N5O6 (403.2431)


   

Lys Val Ala Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]propanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Lys Val Gly Thr

(2S,3R)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]acetamido}-3-hydroxybutanoic acid

C17H33N5O6 (403.2431)


   

Lys Val Ser Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-hydroxypropanamido]propanoic acid

C17H33N5O6 (403.2431)


   

Lys Val Thr Gly

2-[(2S,3R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-hydroxybutanamido]acetic acid

C17H33N5O6 (403.2431)


   
   
   

Leu Gly Lys Ser

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}hexanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Leu Gly Ser Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}-3-hydroxypropanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Leu Lys Gly Ser

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]acetamido}-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Leu Lys Ser Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-hydroxypropanamido]acetic acid

C17H33N5O6 (403.2431)


   

Leu Ser Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]acetamido}hexanoic acid

C17H33N5O6 (403.2431)


   

Leu Ser Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]hexanamido]acetic acid

C17H33N5O6 (403.2431)


   
   
   
   
   

Arg Ala Ala Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]propanamido]-3-hydroxypropanoic acid

C15H29N7O6 (403.2179)


   

Arg Ala Gly Thr

(2S,3R)-2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]acetamido}-3-hydroxybutanoic acid

C15H29N7O6 (403.2179)


   

Arg Ala Ser Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]-3-hydroxypropanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Arg Ala Thr Gly

2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]-3-hydroxybutanamido]acetic acid

C15H29N7O6 (403.2179)


   

Arg Gly Ala Thr

(2S,3R)-2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}propanamido]-3-hydroxybutanoic acid

C15H29N7O6 (403.2179)


   

Arg Gly Thr Ala

(2S)-2-[(2S,3R)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-hydroxybutanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Arg Ser Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]propanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Arg Thr Ala Gly

2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]propanamido]acetic acid

C15H29N7O6 (403.2179)


   

Arg Thr Gly Ala

(2S)-2-{2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]acetamido}propanoic acid

C15H29N7O6 (403.2179)


   

Ser Ala Ala Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]propanamido]propanamido]-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Ser Ala Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]propanamido]hexanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   
   

Ser Ala Arg Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]propanamido]-5-carbamimidamidopentanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Ser Ala Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]propanamido]-3-methylbutanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Ser Gly Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-{2-[(2S)-2-amino-3-hydroxypropanamido]acetamido}-3-methylpentanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Ser Gly Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-hydroxypropanamido]acetamido}hexanamido]-3-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Ser Gly Lys Leu

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-hydroxypropanamido]acetamido}hexanamido]-4-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Ser Gly Leu Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-3-hydroxypropanamido]acetamido}-4-methylpentanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Ser Ile Gly Lys

(2S)-6-amino-2-{2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]acetamido}hexanoic acid

C17H33N5O6 (403.2431)


   

Ser Ile Lys Gly

2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]hexanamido]acetic acid

C17H33N5O6 (403.2431)


   

Ser Lys Ala Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]propanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Ser Lys Gly Ile

(2S,3S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]acetamido}-3-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Ser Lys Gly Leu

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]acetamido}-4-methylpentanoic acid

C17H33N5O6 (403.2431)


   

Ser Lys Ile Gly

2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-methylpentanamido]acetic acid

C17H33N5O6 (403.2431)


   

Ser Lys Leu Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-4-methylpentanamido]acetic acid

C17H33N5O6 (403.2431)


   
   

Ser Lys Val Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-methylbutanamido]propanoic acid

C17H33N5O6 (403.2431)


   

Ser Leu Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]acetamido}hexanoic acid

C17H33N5O6 (403.2431)


   

Ser Leu Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]hexanamido]acetic acid

C17H33N5O6 (403.2431)


   
   

Ser Arg Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]propanamido]propanoic acid

C15H29N7O6 (403.2179)


   
   
   

Ser Val Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanamido]propanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Ser Val Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanamido]hexanamido]propanoic acid

C17H33N5O6 (403.2431)


   

Thr Ala Gly Arg

(2S)-2-{2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]propanamido]acetamido}-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   

Thr Ala Arg Gly

2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]propanamido]-5-carbamimidamidopentanamido]acetic acid

C15H29N7O6 (403.2179)


   

Thr Gly Ala Arg

(2S)-2-[(2S)-2-{2-[(2S,3R)-2-amino-3-hydroxybutanamido]acetamido}propanamido]-5-carbamimidamidopentanoic acid

C15H29N7O6 (403.2179)


   
   

Thr Gly Lys Val

(2S)-2-[(2S)-6-amino-2-{2-[(2S,3R)-2-amino-3-hydroxybutanamido]acetamido}hexanamido]-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Thr Gly Arg Ala

(2S)-2-[(2S)-2-{2-[(2S,3R)-2-amino-3-hydroxybutanamido]acetamido}-5-carbamimidamidopentanamido]propanoic acid

C15H29N7O6 (403.2179)


   

Thr Gly Val Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S,3R)-2-amino-3-hydroxybutanamido]acetamido}-3-methylbutanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Thr Lys Gly Val

(2S)-2-{2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]acetamido}-3-methylbutanoic acid

C17H33N5O6 (403.2431)


   

Thr Lys Val Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-methylbutanamido]acetic acid

C17H33N5O6 (403.2431)


   
   

Thr Arg Ala Gly

2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]propanamido]acetic acid

C15H29N7O6 (403.2179)


   

Thr Arg Gly Ala

(2S)-2-{2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]acetamido}propanoic acid

C15H29N7O6 (403.2179)


   

Thr Val Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]acetamido}hexanoic acid

C17H33N5O6 (403.2431)


   

Thr Val Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]hexanamido]acetic acid

C17H33N5O6 (403.2431)


   

Val Ala Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]hexanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Val Ala Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]-3-hydroxypropanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Val Gly Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}hexanamido]-3-hydroxybutanoic acid

C17H33N5O6 (403.2431)


   

Val Gly Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}-3-hydroxybutanamido]hexanoic acid

C17H33N5O6 (403.2431)


   

Val Lys Ala Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]propanamido]-3-hydroxypropanoic acid

C17H33N5O6 (403.2431)


   

Val Lys Gly Thr

(2S,3R)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]acetamido}-3-hydroxybutanoic acid

C17H33N5O6 (403.2431)


   

Val Lys Ser Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-hydroxypropanamido]propanoic acid

C17H33N5O6 (403.2431)


   

Val Lys Thr Gly

2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-hydroxybutanamido]acetic acid

C17H33N5O6 (403.2431)


   

Val Ser Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxypropanamido]hexanamido]propanoic acid

C17H33N5O6 (403.2431)


   

Val Thr Gly Lys

(2S)-6-amino-2-{2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]acetamido}hexanoic acid

C17H33N5O6 (403.2431)


   

Val Thr Lys Gly

2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]hexanamido]acetic acid

C17H33N5O6 (403.2431)


   

methyl amide

9,11,15R-trihydroxy-16-phenoxy-17,18,19,20-tetranor-prosta-5Z,13E-dien-1-oic acid, methyl amide

C23H33NO5 (403.2359)


   

N-palmitoyl phenylalanine

N-Hexadecanoyl-L-phenlyalanine

C25H41NO3 (403.3086)


   

NA 25:5;O2

N-Hexadecanoyl-L-phenlyalanine

C25H41NO3 (403.3086)


   

NAT 19:1

N-(9Z-nonadecenoyl) taurine

C21H41NO4S (403.2756)


   

Ac-Leu-Val-Phe-aldehyde

Ac-Leu-Val-Phe-aldehyde

C22H33N3O4 (403.2471)


   

ACETIC ACID (2S,3S)-3-DIBENZYLAMINO-2-HYDROXY-4-PHENYLBUTYL ESTER

ACETIC ACID (2S,3S)-3-DIBENZYLAMINO-2-HYDROXY-4-PHENYLBUTYL ESTER

C26H29NO3 (403.2147)


   

ACETIC ACID (2R,3S)-3-DIBENZYLAMINO-2-HYDROXY-4-PHENYLBUTYL ESTER

ACETIC ACID (2R,3S)-3-DIBENZYLAMINO-2-HYDROXY-4-PHENYLBUTYL ESTER

C26H29NO3 (403.2147)


   

bis(2-hydroxyethyl)methyloctylammonium toluene-p-sulphonate

bis(2-hydroxyethyl)methyloctylammonium toluene-p-sulphonate

C20H37NO5S (403.2392)


   

benzyl 3-[3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]azetidin-1-yl]piperidine-1-carboxylate

benzyl 3-[3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]azetidin-1-yl]piperidine-1-carboxylate

C22H33N3O4 (403.2471)


   

Azepino[4,5-b]indole-5-carboxylic acid, 1,2,3,6-tetrahydro-1,1-dimethyl-8-[methyl(phenylmethyl)amino]-, ethyl ester

Azepino[4,5-b]indole-5-carboxylic acid, 1,2,3,6-tetrahydro-1,1-dimethyl-8-[methyl(phenylmethyl)amino]-, ethyl ester

C25H29N3O2 (403.226)


   

1H-Indole-1-carboxylic acid, 3-(1-cyano-1-methylethyl)-6-[methyl(phenylmethyl)amino]-, 1,1-dimethylethyl ester

1H-Indole-1-carboxylic acid, 3-(1-cyano-1-methylethyl)-6-[methyl(phenylmethyl)amino]-, 1,1-dimethylethyl ester

C25H29N3O2 (403.226)


   

(4-cyanophenyl) 4-(4-heptylcyclohexyl)benzoate

(4-cyanophenyl) 4-(4-heptylcyclohexyl)benzoate

C27H33NO2 (403.2511)


   

[5-[[[3-(dimethylamino)-2,2-dimethylpropyl]amino]methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid

[5-[[[3-(dimethylamino)-2,2-dimethylpropyl]amino]methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid

C21H34BN3O4 (403.2642)


   

[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid

[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid

C20H30BN3O5 (403.2278)


   
   

dicyclohexyl-[2-(2-methylphenyl)indol-1-yl]phosphane

dicyclohexyl-[2-(2-methylphenyl)indol-1-yl]phosphane

C27H34NP (403.2429)


   

2-[4-(Boc-amino)-1-piperidinyl]pyridine-5-boronic acid pinacol ester

2-[4-(Boc-amino)-1-piperidinyl]pyridine-5-boronic acid pinacol ester

C21H34BN3O4 (403.2642)


   

N-Hexadecanoyl-D-phenylalanine

N-Hexadecanoyl-D-phenylalanine

C25H41NO3 (403.3086)


   
   

Ethyldimethyl(9-Octadecenyl)Ammonium Bromide

Ethyldimethyl(9-Octadecenyl)Ammonium Bromide

C22H46BrN (403.2813)


   

2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium acetate

2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium acetate

C25H29N3O2 (403.226)


   

NAPHTHOL AS NONANOATE

NAPHTHOL AS NONANOATE

C26H29NO3 (403.2147)


   

TERT-BUTYL 4-(3-METHYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLATE

TERT-BUTYL 4-(3-METHYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLATE

C21H34BN3O4 (403.2642)


   

(+)-N-Acetyl 3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-β][1,4]oxazine-9-ol Triisopropylsilyl Ether

(+)-N-Acetyl 3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-β][1,4]oxazine-9-ol Triisopropylsilyl Ether

C23H37NO3Si (403.2543)


   

Poly(styrene-co-4-bromostyrene-co-divinylbenzene)

Poly(styrene-co-4-bromostyrene-co-divinylbenzene)

C25H29N3O2 (403.226)


   
   

tert-Butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-carboxylate

tert-Butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-carboxylate

C21H34BN3O4 (403.2642)


   
   

Amotriphene

Amotriphene

C26H29NO3 (403.2147)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent

   

N-((2-Methoxypyridin-4-yl)methyl)-1-(1-(naphthalen-1-yl)ethyl)piperidine-4-carboxamide

N-((2-Methoxypyridin-4-yl)methyl)-1-(1-(naphthalen-1-yl)ethyl)piperidine-4-carboxamide

C25H29N3O2 (403.226)


   

(R)-N-((2-Methoxypyridin-4-yl)methyl)-1-(1-(naphthalen-1-yl)ethyl)piperidine-4-carboxamide

(R)-N-((2-Methoxypyridin-4-yl)methyl)-1-(1-(naphthalen-1-yl)ethyl)piperidine-4-carboxamide

C25H29N3O2 (403.226)


   

L-Alanyl-L-lysyl-L-tryptophan

L-Alanyl-L-lysyl-L-tryptophan

C20H29N5O4 (403.2219)


   

progesterone-17-ol-3-CMO

progesterone-17-ol-3-CMO

C23H33NO5 (403.2359)


   

Methyl 4-{[({[(2R,5S)-5-{[(2S)-2-(aminomethyl)pyrrolidin-1-YL]carbonyl}pyrrolidin-2-YL]methyl}amino)carbonyl]amino}benzoate

Methyl 4-{[({[(2R,5S)-5-{[(2S)-2-(aminomethyl)pyrrolidin-1-YL]carbonyl}pyrrolidin-2-YL]methyl}amino)carbonyl]amino}benzoate

C20H29N5O4 (403.2219)


   

7alpha,12alpha-Dihydroxy-3-oxochol-4-en-24-oate

7alpha,12alpha-Dihydroxy-3-oxochol-4-en-24-oate

C24H35O5- (403.2484)


   

3 beta-Hydroxy-7,12-diketocholanate

3 beta-Hydroxy-7,12-diketocholanate

C24H35O5- (403.2484)


   

3,7-Dihydroxytetradecanoylcarnitine

3,7-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,8-Dihydroxytetradecanoylcarnitine

3,8-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,4-Dihydroxytetradecanoylcarnitine

3,4-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,5-Dihydroxytetradecanoylcarnitine

3,5-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,6-Dihydroxytetradecanoylcarnitine

3,6-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,9-Dihydroxytetradecanoylcarnitine

3,9-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,11-Dihydroxytetradecanoylcarnitine

3,11-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,13-Dihydroxytetradecanoylcarnitine

3,13-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,10-Dihydroxytetradecanoylcarnitine

3,10-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

3,12-Dihydroxytetradecanoylcarnitine

3,12-Dihydroxytetradecanoylcarnitine

C21H41NO6 (403.2934)


   

N-Arachidonoyl Valine

N-Arachidonoyl Valine

C25H41NO3 (403.3086)


   

N-Eicosapentaenoyl Threonine

N-Eicosapentaenoyl Threonine

C24H37NO4 (403.2722)


   
   

N-oleoylethanolamine phosphate(2-)

N-oleoylethanolamine phosphate(2-)

C20H38NO5P-2 (403.2487)


   
   

2-(3,5-dimethyl-1-pyrazolyl)-N-[[3-(4-fluorophenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]ethanamine

2-(3,5-dimethyl-1-pyrazolyl)-N-[[3-(4-fluorophenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]ethanamine

C24H26FN5 (403.2172)


   

3alpha-Hydroxy-7,12-dioxo-5beta-cholanate

3alpha-Hydroxy-7,12-dioxo-5beta-cholanate

C24H35O5- (403.2484)


   

7beta-Hydroxy-3,12-dioxo-5beta-cholanate

7beta-Hydroxy-3,12-dioxo-5beta-cholanate

C24H35O5- (403.2484)


   

7alpha-Hydroxy-3,12-dioxo-5beta-cholanate

7alpha-Hydroxy-3,12-dioxo-5beta-cholanate

C24H35O5- (403.2484)


   
   
   
   
   
   

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C22H33N3O4 (403.2471)


   

(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

C23H37N3O3 (403.2835)


   

(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

C23H37N3O3 (403.2835)


   

(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

C23H37N3O3 (403.2835)


   

N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C22H33N3O4 (403.2471)


   

2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-phenyl-1-piperazinyl)ethanone

2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-phenyl-1-piperazinyl)ethanone

C22H33N3O4 (403.2471)


   

(3aS,4R,9bR)-4-(hydroxymethyl)-5-methyl-8-(2-phenylethynyl)-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

(3aS,4R,9bR)-4-(hydroxymethyl)-5-methyl-8-(2-phenylethynyl)-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

C25H29N3O2 (403.226)


   

[(8S,9R,10S)-9-[4-(1-cyclopentenyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

[(8S,9R,10S)-9-[4-(1-cyclopentenyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C26H33N3O (403.2623)


   

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide

C22H33N3O4 (403.2471)


   

(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

C23H37N3O3 (403.2835)


   

(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2,3,4,7-tetrahydro-1,5-benzoxazonin-6-one

C23H37N3O3 (403.2835)


   

N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C22H33N3O4 (403.2471)


   

N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide

C22H33N3O4 (403.2471)


   

(3aR,4S,9bS)-4-(hydroxymethyl)-5-methyl-8-(2-phenylethynyl)-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

(3aR,4S,9bS)-4-(hydroxymethyl)-5-methyl-8-(2-phenylethynyl)-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

C25H29N3O2 (403.226)


   

[(8R,9S,10R)-9-[4-(1-cyclopentenyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

[(8R,9S,10R)-9-[4-(1-cyclopentenyl)phenyl]-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C26H33N3O (403.2623)


   

4-[4-[(1S,5R)-3-[cyclobutyl(oxo)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide

4-[4-[(1S,5R)-3-[cyclobutyl(oxo)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide

C25H29N3O2 (403.226)


   

N-[4-(2,3,9,9-tetramethyl-7-oxo-6,6a,8,10-tetrahydro-5H-benzo[b][1,4]benzodiazepin-6-yl)phenyl]acetamide

N-[4-(2,3,9,9-tetramethyl-7-oxo-6,6a,8,10-tetrahydro-5H-benzo[b][1,4]benzodiazepin-6-yl)phenyl]acetamide

C25H29N3O2 (403.226)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

(3R)-15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxypentadecanoate

(3R)-15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxypentadecanoate

C21H39O7- (403.2696)


   

(3R,14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxypentadecanoate

(3R,14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxypentadecanoate

C21H39O7- (403.2696)


   
   

(4Z,7Z,10Z,13Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

C25H41NO3 (403.3086)


   

2-(14-Methylpentadecanoylamino)-3-phenylpropanoic acid

2-(14-Methylpentadecanoylamino)-3-phenylpropanoic acid

C25H41NO3 (403.3086)


   

4-(3-Acetyloxy-2-octanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Acetyloxy-2-octanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C20H37NO7 (403.257)


   

4-[2,3-Di(pentanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate

4-[2,3-Di(pentanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate

C20H37NO7 (403.257)


   

4-(2-Heptanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(2-Heptanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C20H37NO7 (403.257)


   

4-(3-Butanoyloxy-2-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(3-Butanoyloxy-2-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C20H37NO7 (403.257)


   

2-(2-Trimethylsilyloxyethoxy)-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

2-(2-Trimethylsilyloxyethoxy)-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

C21H33N3O3Si (403.2291)


   

7,12-dioxolithocholate

7,12-dioxolithocholate

C24H35O5 (403.2484)


A cholanic acid anion that is the conjugate base of 7,12-dioxolithocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

bhos#26(1-)

bhos#26(1-)

C21H39O7 (403.2696)


Conjugate base of bhos#26

   

bhas#26(1-)

bhas#26(1-)

C21H39O7 (403.2696)


Conjugate base of bhas#26

   

NA-Ala 22:4(7Z,10Z,13Z,16Z)

NA-Ala 22:4(7Z,10Z,13Z,16Z)

C25H41NO3 (403.3086)


   

NA-Dopamine 17:1(9Z)

NA-Dopamine 17:1(9Z)

C25H41NO3 (403.3086)


   

NA-His 17:2(9Z,12Z)

NA-His 17:2(9Z,12Z)

C23H37N3O3 (403.2835)


   
   
   

NA-Taurine 19:1(9Z)

NA-Taurine 19:1(9Z)

C21H41NO4S (403.2756)


   

NA-Thr 20:5(5Z,8Z,11Z,14Z,17Z)

NA-Thr 20:5(5Z,8Z,11Z,14Z,17Z)

C24H37NO4 (403.2722)


   

NA-Tyr 15:1(9Z)

NA-Tyr 15:1(9Z)

C24H37NO4 (403.2722)


   

NA-Val 20:4(5Z,8Z,11Z,14Z)

NA-Val 20:4(5Z,8Z,11Z,14Z)

C25H41NO3 (403.3086)


   
   
   
   

ST 21:3;O3;Gly

ST 21:3;O3;Gly

C23H33NO5 (403.2359)


   

ST 22:2;O2;Gly

ST 22:2;O2;Gly

C24H37NO4 (403.2722)


   

methyl 6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl 6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H37NO4 (403.2722)


   

1-(8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,12-dien-1-yl)-3-phenylprop-2-en-1-one

1-(8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,12-dien-1-yl)-3-phenylprop-2-en-1-one

C25H29N3O2 (403.226)


   

methyl (1'r,3r,5's,6s,7's)-6-ethyl-6,7'-dihydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate

methyl (1'r,3r,5's,6s,7's)-6-ethyl-6,7'-dihydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate

C23H33NO5 (403.2359)


   

(1s,2s,4r,5s,7r,12s,16s)-14-ethyl-5,16-dimethoxy-12-(methoxymethyl)-14-azapentacyclo[10.3.3.1⁴,⁷.0¹,¹¹.0²,⁷]nonadec-10-en-19-one

(1s,2s,4r,5s,7r,12s,16s)-14-ethyl-5,16-dimethoxy-12-(methoxymethyl)-14-azapentacyclo[10.3.3.1⁴,⁷.0¹,¹¹.0²,⁷]nonadec-10-en-19-one

C24H37NO4 (403.2722)


   

(2s)-2-{[(2e,4e,6r)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

(2s)-2-{[(2e,4e,6r)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

C23H33NO5 (403.2359)


   

(2s)-2-{[(2e,4e,6s)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

(2s)-2-{[(2e,4e,6s)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

C23H33NO5 (403.2359)


   

(1's,3r,5'r,6s,11's,12's)-6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

(1's,3r,5'r,6s,11's,12's)-6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

C24H37NO4 (403.2722)


   

(2e)-1-[(6r,10e)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one

(2e)-1-[(6r,10e)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one

C25H29N3O2 (403.226)


   

methyl 6-ethyl-6,7'-dihydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate

methyl 6-ethyl-6,7'-dihydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate

C23H33NO5 (403.2359)


   

11-ethyl-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-7-en-16-ol

11-ethyl-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-7-en-16-ol

C24H37NO4 (403.2722)


   

2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate

2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate

C23H33NO5 (403.2359)


   

methyl 6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl 6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H33NO5 (403.2359)


   

(1'r,3r,5's,6r,11'r,12'r)-6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

(1'r,3r,5's,6r,11'r,12'r)-6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

C24H37NO4 (403.2722)


   

5-hydroxy-4-{hydroxy[6-hydroxy-1,3,6-trimethyl-2-(prop-1-en-1-yl)-2,4a,5,7,8,8a-hexahydronaphthalen-1-yl]methylidene}-2-(1-hydroxyethyl)-2h-pyrrol-3-one

5-hydroxy-4-{hydroxy[6-hydroxy-1,3,6-trimethyl-2-(prop-1-en-1-yl)-2,4a,5,7,8,8a-hexahydronaphthalen-1-yl]methylidene}-2-(1-hydroxyethyl)-2h-pyrrol-3-one

C23H33NO5 (403.2359)


   

methyl 6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl 6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H37NO4 (403.2722)


   

5-[(1s)-1-hydroxy-3-{[(2e,4s,6r)-1-hydroxy-4,6,8-trimethylnona-2,7-dien-1-ylidene]amino}-4-oxocyclohexa-2,5-dien-1-yl]pentanoic acid

5-[(1s)-1-hydroxy-3-{[(2e,4s,6r)-1-hydroxy-4,6,8-trimethylnona-2,7-dien-1-ylidene]amino}-4-oxocyclohexa-2,5-dien-1-yl]pentanoic acid

C23H33NO5 (403.2359)


   

(2s,4e)-4-{[(1s,2r,4as,6r,8ar)-6-hydroxy-1,3,6-trimethyl-2-[(1e)-prop-1-en-1-yl]-2,4a,5,7,8,8a-hexahydronaphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-[(1r)-1-hydroxyethyl]-2h-pyrrol-3-one

(2s,4e)-4-{[(1s,2r,4as,6r,8ar)-6-hydroxy-1,3,6-trimethyl-2-[(1e)-prop-1-en-1-yl]-2,4a,5,7,8,8a-hexahydronaphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-[(1r)-1-hydroxyethyl]-2h-pyrrol-3-one

C23H33NO5 (403.2359)


   

methyl (1'r,3r,5's,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1'r,3r,5's,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H37NO4 (403.2722)


   

(2e)-1-[(6s,12z)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,12-dien-1-yl]-3-phenylprop-2-en-1-one

(2e)-1-[(6s,12z)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,12-dien-1-yl]-3-phenylprop-2-en-1-one

C25H29N3O2 (403.226)


   

(2r,3r,4s,7r,8s,12r,15s)-4,7,8,16,16-pentamethyl-22-azahexacyclo[15.6.1.0²,¹⁵.0³,¹².0⁷,¹².0²¹,²⁴]tetracosa-1(23),17(24),18,20-tetraen-11-one

(2r,3r,4s,7r,8s,12r,15s)-4,7,8,16,16-pentamethyl-22-azahexacyclo[15.6.1.0²,¹⁵.0³,¹².0⁷,¹².0²¹,²⁴]tetracosa-1(23),17(24),18,20-tetraen-11-one

C28H37NO (403.2875)


   

n-{1-[7-(acetyloxy)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl}ethanimidic acid

n-{1-[7-(acetyloxy)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl}ethanimidic acid

C25H41NO3 (403.3086)


   

5-[(2z,6z)-10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl]-3h-isoindole-1,4,6-triol

5-[(2z,6z)-10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl]-3h-isoindole-1,4,6-triol

C23H33NO5 (403.2359)


   

methyl (1'r,3r,5's,6r,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1'r,3r,5's,6r,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H33NO5 (403.2359)


   

1,2,9-trimethyl-7-(2-methylprop-1-en-1-yl)-6-oxa-22-azahexacyclo[11.10.0.0²,¹⁰.0⁵,⁹.0¹⁵,²³.0¹⁶,²¹]tricosa-15(23),16,18,20-tetraene

1,2,9-trimethyl-7-(2-methylprop-1-en-1-yl)-6-oxa-22-azahexacyclo[11.10.0.0²,¹⁰.0⁵,⁹.0¹⁵,²³.0¹⁶,²¹]tricosa-15(23),16,18,20-tetraene

C28H37NO (403.2875)


   

(1s,2r,3s,4s,5r,6s,9r,10r,13s,16r,17r)-11-ethyl-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-7-en-16-ol

(1s,2r,3s,4s,5r,6s,9r,10r,13s,16r,17r)-11-ethyl-4,6-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-7-en-16-ol

C24H37NO4 (403.2722)


   

methyl (1'r,3r,5's,6s,11's,12's)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1'r,3r,5's,6s,11's,12's)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H37NO4 (403.2722)


   

2-[(1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

2-[(1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

C23H33NO5 (403.2359)


   

9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one

9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one

C25H29N3O2 (403.226)


   

methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H33NO5 (403.2359)


   

(2z)-1-[(6r,10e)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one

(2z)-1-[(6r,10e)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one

C25H29N3O2 (403.226)


   

15-isopropyl-18,19-dimethyl-11-azahexacyclo[13.7.2.0¹,¹⁸.0²,¹⁴.0⁴,¹².0⁵,¹⁰]tetracosa-2(14),4(12),5,7,9-pentaen-22-ol

15-isopropyl-18,19-dimethyl-11-azahexacyclo[13.7.2.0¹,¹⁸.0²,¹⁴.0⁴,¹².0⁵,¹⁰]tetracosa-2(14),4(12),5,7,9-pentaen-22-ol

C28H37NO (403.2875)


   

2-{[(2e,4e)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

2-{[(2e,4e)-1,12-dihydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

C23H33NO5 (403.2359)


   

5-{1-hydroxy-3-[(1-hydroxy-4,6,8-trimethylnona-2,7-dien-1-ylidene)amino]-4-oxocyclohexa-2,5-dien-1-yl}pentanoic acid

5-{1-hydroxy-3-[(1-hydroxy-4,6,8-trimethylnona-2,7-dien-1-ylidene)amino]-4-oxocyclohexa-2,5-dien-1-yl}pentanoic acid

C23H33NO5 (403.2359)


   

(7r,13r)-9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one

(7r,13r)-9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one

C25H29N3O2 (403.226)


   

methyl (1r,3r,4r,10r,14r,15r,17r,18s,19r)-17,19-dihydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate

methyl (1r,3r,4r,10r,14r,15r,17r,18s,19r)-17,19-dihydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate

C23H33NO5 (403.2359)


   

n-[(1s)-1-[(1r,3as,3br,5as,7s,9as,9bs,11as)-7-(acetyloxy)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl]ethanimidic acid

n-[(1s)-1-[(1r,3as,3br,5as,7s,9as,9bs,11as)-7-(acetyloxy)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl]ethanimidic acid

C25H41NO3 (403.3086)


   

methyl (1's,3s,5'r,6s,11'r,12's)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1's,3s,5'r,6s,11'r,12's)-6-ethyl-6-hydroxy-3'-methyl-7'-oxo-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C23H33NO5 (403.2359)


   

(1s,2s,5s,7r,9s,10r,13s)-1,2,9-trimethyl-7-(2-methylprop-1-en-1-yl)-6-oxa-22-azahexacyclo[11.10.0.0²,¹⁰.0⁵,⁹.0¹⁵,²³.0¹⁶,²¹]tricosa-15(23),16,18,20-tetraene

(1s,2s,5s,7r,9s,10r,13s)-1,2,9-trimethyl-7-(2-methylprop-1-en-1-yl)-6-oxa-22-azahexacyclo[11.10.0.0²,¹⁰.0⁵,⁹.0¹⁵,²³.0¹⁶,²¹]tricosa-15(23),16,18,20-tetraene

C28H37NO (403.2875)


   

(1s,15r,18s,19r,22s)-15-isopropyl-18,19-dimethyl-11-azahexacyclo[13.7.2.0¹,¹⁸.0²,¹⁴.0⁴,¹².0⁵,¹⁰]tetracosa-2(14),4(12),5,7,9-pentaen-22-ol

(1s,15r,18s,19r,22s)-15-isopropyl-18,19-dimethyl-11-azahexacyclo[13.7.2.0¹,¹⁸.0²,¹⁴.0⁴,¹².0⁵,¹⁰]tetracosa-2(14),4(12),5,7,9-pentaen-22-ol

C28H37NO (403.2875)


   

methyl (1's,3r,5'r,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1's,3r,5'r,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H37NO4 (403.2722)


   

(2e)-1-[(6s,10z)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one

(2e)-1-[(6s,10z)-8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl]-3-phenylprop-2-en-1-one

C25H29N3O2 (403.226)


   

methyl (1's,3s,5'r,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1's,3s,5'r,6r,11'r,12'r)-6-hydroxy-6-isopropyl-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H37NO4 (403.2722)


   

4,7,8,16,16-pentamethyl-22-azahexacyclo[15.6.1.0²,¹⁵.0³,¹².0⁷,¹².0²¹,²⁴]tetracosa-1(23),17(24),18,20-tetraen-11-one

4,7,8,16,16-pentamethyl-22-azahexacyclo[15.6.1.0²,¹⁵.0³,¹².0⁷,¹².0²¹,²⁴]tetracosa-1(23),17(24),18,20-tetraen-11-one

C28H37NO (403.2875)


   

4,4a-dimethyl-13b-(4-methylpent-3-en-1-yl)-1h,2h,3h,4h,5h,6h,7h,8h,13h-naphtho[2,1-b]carbazol-1-ol

4,4a-dimethyl-13b-(4-methylpent-3-en-1-yl)-1h,2h,3h,4h,5h,6h,7h,8h,13h-naphtho[2,1-b]carbazol-1-ol

C28H37NO (403.2875)


   

(1s,4r,4as,13br)-4,4a-dimethyl-13b-(4-methylpent-3-en-1-yl)-1h,2h,3h,4h,5h,6h,7h,8h,13h-naphtho[2,1-b]carbazol-1-ol

(1s,4r,4as,13br)-4,4a-dimethyl-13b-(4-methylpent-3-en-1-yl)-1h,2h,3h,4h,5h,6h,7h,8h,13h-naphtho[2,1-b]carbazol-1-ol

C28H37NO (403.2875)


   

methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1'r,3r,5's,6s,11'r,12'r)-6-ethyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H37NO4 (403.2722)


   

5-(10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl)-3h-isoindole-1,4,6-triol

5-(10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl)-3h-isoindole-1,4,6-triol

C23H33NO5 (403.2359)


   

(1r,2s,5s,8r,9r,10s,11s,12s,13r,15r,16r,18s)-2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate

(1r,2s,5s,8r,9r,10s,11s,12s,13r,15r,16r,18s)-2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate

C23H33NO5 (403.2359)


   

2-amino-n-[4-amino-3-({3-amino-6-[(ethylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide

2-amino-n-[4-amino-3-({3-amino-6-[(ethylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide

C18H37N5O5 (403.2795)


   

(7s,13r)-9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one

(7s,13r)-9-hydroxy-7-phenyl-1,6,10-triazatricyclo[11.9.0.0¹⁴,¹⁹]docosa-9,14,16,18,20-pentaen-22-one

C25H29N3O2 (403.226)


   

methyl (1r,3r,4r,10s,14s,15r,17r,18s,19r)-17,19-dihydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate

methyl (1r,3r,4r,10s,14s,15r,17r,18s,19r)-17,19-dihydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate

C23H33NO5 (403.2359)


   

6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

6-isopropyl-6-methoxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylic acid

C24H37NO4 (403.2722)


   

(1r,2s,5s,8r,9r,11s,12s,13r,15r,16r,18s)-2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate

(1r,2s,5s,8r,9r,11s,12s,13r,15r,16r,18s)-2,11-dihydroxy-5,7-dimethyl-7-azaspiro[hexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-12,2'-oxiran]-18-yl acetate

C23H33NO5 (403.2359)


   

14-ethyl-5,16-dimethoxy-12-(methoxymethyl)-14-azapentacyclo[10.3.3.1⁴,⁷.0¹,¹¹.0²,⁷]nonadec-10-en-19-one

14-ethyl-5,16-dimethoxy-12-(methoxymethyl)-14-azapentacyclo[10.3.3.1⁴,⁷.0¹,¹¹.0²,⁷]nonadec-10-en-19-one

C24H37NO4 (403.2722)


   

1-[(1s,2r,3r,4s,5s,6s,8r,9s,10r,13r,16s,17r)-11-ethyl-8,16-dihydroxy-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl]ethanone

1-[(1s,2r,3r,4s,5s,6s,8r,9s,10r,13r,16s,17r)-11-ethyl-8,16-dihydroxy-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl]ethanone

C24H37NO4 (403.2722)


   

(5r)-3-methyl-5-[(1s,2r,3s,4s,6r,11s)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.4.0.0²,⁶]tetradecan-4-yl]-5h-furan-2-one

(5r)-3-methyl-5-[(1s,2r,3s,4s,6r,11s)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.4.0.0²,⁶]tetradecan-4-yl]-5h-furan-2-one

C23H33NO5 (403.2359)


   

methyl 3-[(3s,3ar,5ar,8ar,11br,11cs)-1-formyl-5a-(hydroxymethyl)-3-methyl-6-oxo-2h,3h,3ah,4h,5h,7h,8h,8ah,9h,10h,11ch-azuleno[5,4-g]indol-11b-yl]propanoate

methyl 3-[(3s,3ar,5ar,8ar,11br,11cs)-1-formyl-5a-(hydroxymethyl)-3-methyl-6-oxo-2h,3h,3ah,4h,5h,7h,8h,8ah,9h,10h,11ch-azuleno[5,4-g]indol-11b-yl]propanoate

C23H33NO5 (403.2359)


   

1-(8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl)-3-phenylprop-2-en-1-one

1-(8-hydroxy-6-phenyl-1,5,9-triazacyclotrideca-8,10-dien-1-yl)-3-phenylprop-2-en-1-one

C25H29N3O2 (403.226)


   

methyl 3-[1-formyl-5a-(hydroxymethyl)-3-methyl-6-oxo-2h,3h,3ah,4h,5h,7h,8h,8ah,9h,10h,11ch-azuleno[5,4-g]indol-11b-yl]propanoate

methyl 3-[1-formyl-5a-(hydroxymethyl)-3-methyl-6-oxo-2h,3h,3ah,4h,5h,7h,8h,8ah,9h,10h,11ch-azuleno[5,4-g]indol-11b-yl]propanoate

C23H33NO5 (403.2359)